Related Experiment Video
Updated: Jun 9, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
A target-response ratiometric or turn-off fluorescent dual-mode platform for simultaneous detection of multiple
Da-Qian Feng1, Wenfeng Zhang1, Zhendi Yu1
1School of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng 224051, China.
Abstract:
The anthracycline including doxorubicin (DOX), daunorubicin (DAU) and mitoxantrone (MTX) plays crucial roles in human health due to their notably clinical efficacy in various malignant tumors. There is few molecular probe and abiotic sensor that can simultaneously discriminate among anthracycline drugs. Herein, a target-response ratiometric and turn-off fluorescent dual-mode platform was designed for simultaneous detection of multiple anticancer drugs based on blue-emitting carbon dots (BCDs). In the presence of anthracycline, specific absorption and formation of the BCDs-anthracycline conjugate was achieved via electrostatic interaction and hydrophobic force, leading to ratiometric signal or quenched fluorescent response, thereby achieving ratiometric or turn-off dual-mode detection. Specifically, the introduction of both DOX and DAU produce ratiometric response of BCDs due to fluorescence resonance energy transfer (FRET) and dynamic quenching while MTX only induce reduced fluorescent response attribute to photoinduced electron transfer (PET) and dynamic quenching. The linear range calculated is 1-98, 1-91 and 1-77 μM for DOX, DAU and MTX, respectively, with a limit of detection of 0.02, 0.05 and 0.06 μM. Taking advantage of target-response self-verification ratiometric and sensitive fluorescent detection, the dual-mode platform was proposed and applied for successful discrimination of anthracycline drugs. This study opens a new path for multiplex drugs analysis in a facile and rapid way.
Insights
A new dual-mode fluorescent platform using blue-emitting carbon dots (BCDs) enables simultaneous detection and discrimination of anthracycline anticancer drugs like doxorubicin (DOX) and daunorubicin (DAU). This method offers a facile and rapid approach for multiplex drug analysis.
Area of Science:
- Analytical Chemistry
- Materials Science
- Biomedical Engineering
Background:
- Anthracyclines like doxorubicin (DOX), daunorubicin (DAU), and mitoxantrone (MTX) are vital anticancer drugs with significant clinical efficacy.
- Existing molecular probes and sensors struggle with simultaneous discrimination among different anthracycline drugs.
- Accurate and simultaneous quantification of these drugs is crucial for effective cancer therapy and monitoring.
Purpose of the Study:
- To develop a novel dual-mode fluorescent platform for the simultaneous detection and discrimination of multiple anthracycline anticancer drugs.
- To utilize blue-emitting carbon dots (BCDs) as a core component for a sensitive and selective sensing system.
- To establish a facile and rapid analytical method for complex drug mixture analysis.
Main Methods:
- Design and synthesis of blue-emitting carbon dots (BCDs).
- Development of a target-response ratiometric and turn-off fluorescent dual-mode detection platform.
- Investigation of interactions (electrostatic, hydrophobic) between BCDs and anthracyclines (DOX, DAU, MTX).
- Utilizing fluorescence resonance energy transfer (FRET), dynamic quenching, and photoinduced electron transfer (PET) mechanisms for signal generation.
Main Results:
- The platform achieved simultaneous detection of DOX, DAU, and MTX with distinct fluorescent responses (ratiometric for DOX/DAU, turn-off for MTX).
- Linear detection ranges were established: 1-98 μM for DOX, 1-91 μM for DAU, and 1-77 μM for MTX.
- Low limits of detection were achieved: 0.02 μM for DOX, 0.05 μM for DAU, and 0.06 μM for MTX.
- Successful discrimination of anthracycline drugs in a multiplex manner was demonstrated.
Conclusions:
- The developed dual-mode fluorescent platform based on BCDs provides a sensitive, selective, and rapid method for simultaneous analysis of multiple anthracycline drugs.
- The platform leverages target-response self-verification for reliable detection.
- This study presents a promising new avenue for multiplex drug analysis in clinical and research settings.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...